Campbell & Co Investment Adviser’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Campbell & Co Investment Adviser’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-10,514	Closed	-$651K	–	1062
2022 Q3	$651K	Buy	10,514 +7,711	+275%	+$539K	0.15%	229
2022 Q2	$224K	Buy	+2,803	New	+$265K	0.06%	568
2019 Q2	–	Sell	-8,375	Closed	-$221K	–	781
2019 Q1	$221K	Buy	+8,375	New	+$198K	0.11%	404

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Campbell & Co Investment Adviser's HZNP Position: Q4 2022 in Review

Campbell & Co Investment Adviser sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 10,514 shares — an estimated $651K sold.

Campbell & Co Investment Adviser first reported a position in HZNP in Q1 2019 and held it in 3 quarters. The position peaked at $651K in Q3 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Campbell & Co Investment Adviser reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Campbell & Co Investment Adviser sold 10,514 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $651K.
Campbell & Co Investment Adviser first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2019 and held it in 3 quarters.
Campbell & Co Investment Adviser's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $651K in Q3 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2022, filed 14 Feb 2023.